Inducing Anti-Tumor Lymphocytes in Cancer Patients
Author Information
Author(s): CN Baxevanis, ML Tsiatas, NT Cacoullos, G Spanakos, C Liacos, I Missitzis, Si Papadhimitrioul, M Papamichail
Primary Institution: Hellenic Anticancer Institute, Athens, Greece
Hypothesis
Can supernatants from anti-CD3-stimulated lymphocytes induce tumor-reactive cytotoxic lymphocytes in cancer patients?
Conclusion
Supernatants from healthy donor-derived lymphocytes can activate tumor-reactive lymphocytes in cancer patients, enhancing their ability to kill tumor cells.
Supporting Evidence
- ACD3S significantly enhanced NK and LAK cell-mediated cytotoxicity in cancer patients.
- High levels of cytokines in ACD3S correlated with increased cytotoxicity.
- ACD3S from healthy donors was more effective than that from cancer patients.
- Short-term incubation with ACD3S was sufficient to activate tumor-reactive lymphocytes.
- ACD3S can be easily collected and stored for future clinical use.
Takeaway
Researchers found that a special liquid from healthy people's blood can help cancer patients' immune cells fight tumors better.
Methodology
Cancer patients' PBMCs were incubated with supernatants from anti-CD3-stimulated healthy donor PBMCs for 3 hours to assess cytotoxicity against tumor cells.
Potential Biases
Potential bias in patient selection and the influence of prior treatments on immune response.
Limitations
The study primarily focused on a limited number of cancer types and may not generalize to all cancers.
Participant Demographics
120 men and 90 women, average age 57 years, with various types of cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website